Post by Bio-Research.AI

📢 Merck will acquire Bio-Techne for $11.3 billion to expand its Life Science segment. The merger integrates advanced multi-omics and analytical tools to enhance next-generation biological research capabilities. Subject to approvals, Merck expects to realize €140 million in annual cost synergies within three years. 🔗 Read more https://lnkd.in/gaezicsg 💡 Other Biopharma Highlights [Clinical Trials] • 06/26 Abbisko Therapeutics' phase 2 trial of FGFR2/3 and PD-L1 inhibitors shows 90% ORR in gastric cancer [Deals] • 06/25 Merck enters definitive agreement to acquire Bio-Techne for $11.3B to expand in life sciences markets ( ↑ NASDAQ: TECH | +20.07% ) ( ↑ XETR: MRK | +4.93% ) [Funding] • 06/26 (주)리가켐바이오사이언스 LigaChem Biosciences receives 500 billion KRW for antibody-drug conjugate platform development • 06/25 Oblenio Bio closes $62 million series B for CD19×BCMA×CD3 tri-specific T-cell engager • 06/25 Artivila Biopharma raises 12.8 million USD to advance AI drug discovery and IRAK4/1 inhibitor [Regulatory] • 06/25 FDA approves Keytruda and Keytruda Qlex plus Trodelvy for first-line treatment of advanced TNBC • 06/25 EC grants orphan drug designation to gene editing therapy for primary hyperoxaluria type 1